Nanologica AB (publ) (NICA) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Headline then, we have delivered our products finally to customers, both to incident manufacturers and to customers in China who have paid. We have received an order for a silica-based product, a lab sieve, for 3.6 million SEK and we have strengthened the production team in Södertälje and also in the factory. Then, after the release of the period, we have announced a preferred emission. A little about figures then. 1.4 million is a little over in sales, especially columns, a little silica here at the end. Minus 70 million in turnover results, minus 75 result after tax and 10 million at the beginning of the period in the cash register. I would also like to comment on two slightly larger descriptions we do. We have one of 5 million that is a medical care project that we have put on pause and now also concluded. Vi har en nedskrivning på 10 miljoner som egentligen härhör sig från de problem vi har rapporterat om tidigare. Vi har haft ganska stora produktionsproblem. Jag har också berättat att vi har förstört en del material. Det är helt enkelt den typen av material som vi tar bort från balansräkningen. Det gör också att vi går in i 2024 med en väldigt fräsch balansräkning som vi är väldigt nöjda med. In terms of sales, very strong support from existing owners. Technical connection at about 40%. In addition, we actually have four owners who are with me in the warranty consortium and who would like to sell more shares. The external guarantors, there are four of them, are very good, I think. We have met them and they would like to have shares in the company. Totalt på 54,2 miljoner brutto då på 76,5 och det är teckningsperioden 28 februari till 13 mars. Själva det den har tecknat om jag haft möjlighet, min prorata är då 3 miljoner och det har jag tyvärr inte möjlighet att ...